Synairgen Share Discussion Threads

[tburns] 27/3/2020 08:50

Looks like a720k BUY there at 08:47 at well over mid. Must be getting stock that size from somewhere and lets hope whoever has them has them tucked away for the long term

[adman50] 27/3/2020 08:46

Exactly this and has been constantly been reiterated.

This is a game of poker here- gotta hold your never because the pair of aces you're currently holding could easily turn into four of a kind in a few weeks!

[nobbygnome] 27/3/2020 08:31

>> PDT

Thanks for posting. I think that indicates the price will be considerably higher when we get to the results once the placing indigestion is out of the way. Great stuff!

[tidy 2] 27/3/2020 08:25

4m quid batch of SNG001. How many thousands of patients will that cover?Seems they have funded anticipating successCOVID19 to added to the long list of viruses SNG001 can combat.

[pdt] 27/3/2020 08:03

The FinnCap note is well worth a read. Points I found interesting, with my comments in brackets, were;

- Two graphs showing viral load reduction against MERS and Swine Flu (one of the secondary endpoints in the current trial is viral load clearance)

- Patients enrolled on the trial are WHO Ordinal Scale 3 and 4, which is hospitalised mild disease. They will be either patients receiving no oxygen or those that do will be be by mask or nose prongs. (I suspect the best results will be in these patients with enough uninfected cells in their lungs)

- Mention of possible route into US by Emergency Use Authorisation. With comment that safety had already been demonstrated in 230 patients was a big point in SNG001's favour.

- Their calculations are based on assuming that a 10-day course of interferon beta therapy costs c.$5,000. This gives a market opportunity in the UK of $1 billion (This is over the course of this pandemic which I assume could be years. What is the opportunity worldwide?)

- Market opportunity to supply governments worldwide with a stockpile ready for the next virus. They gave Tamiflu as an example and estimated over $3 billion of sales.

- Conservative valuation on success in the current trial of 360p

[andymunchkin] 27/3/2020 01:16

ItAlready has patents forFighting flu in theElderly butIt didn’t stoptheRot from 60p to 10p rinse& repeat again

[andymunchkin] 27/3/2020 01:13

SwineFlu. Tamiflu drama
SameNow rinse&repeat Sng price went frm 60p to 10p
Same gonnaHappen here. 30-40p postDrama. Dump
———;——̵2;——R12;-
andrbea12 Nov '09 - 10:46 - 30 of 51
0 0 0
Isn't the pace of their trials just too slow?

With a proven market for swine flu, copd and asthma, is it prudent to stay independent I wonder? Surely the IFN technology needs to be fast-tracked, either by a full takeover by a major pharma (with the clout to speed up trials, and do them on a larger scale, eg for FSA approval)

... or through franchises of the technology to big pharma
---------------
yet itFell from 60p to 10p

rinse&repeat

[makendon] 26/3/2020 22:42

Found another update from morning star:

www.morningstar.co.uk/uk/news/AN_1585232801683461400/update-synairgen-successfully-raises-cash-for-covid-19-trials

UPDATE: Synairgen Successfully Raises Cash For Covid-19 Trials (Alliance News) - Respiratory drug firm Synairgen PLC confirmed on Thursday it has raised GBP14.0 ...
Alliance News26 March, 2020 | 2:26PM Email Form
(Alliance News) - Respiratory drug firm Synairgen PLC confirmed on Thursday it has raised GBP14.0 million in a share placing.
Synairgen, which first announced the placing on Wednesday, placed 40.0 million new shares at a price of 35 pence each. Shares were 0.1% lower on Thursday afternoon at 46.46p.
The company had said the placing, which was run by finnCap Ltd, will be used to fund Covid-19 trials, making SNG001, and for general working purposes and to strengthen the balance sheet.
On Wednesday, Synairgen said it has received expedited approvals from two UK regulators to trial SNG001 in Covid-19 patients.
"We are delighted with the support for this financing which will enable us to assess SNG001's effectiveness in Covid-19 patients. A successful outcome from the trial would be a major breakthrough in the fight against coronavirus and a significant value-enhancing event for Synairgen and our shareholders," said Chief Executive Richard Marsden.
"Our wholly-owned drug, SNG001, has already been well-tolerated in clinical trials in more than 200 respiratory patients to date and has accelerated lung function recovery in two phase two asthma trials in patients with a cold or flu infection."
"We thank everyone involved for their support, both internally and externally - staff, investigators, regulatory bodies, all our service, product and equipment providers, and our current and new high-quality specialist and generalist shareholders - as we strive to help society during this pandemic," he added.

By George Collard; [e-mail]
Copyright 2020 Alliance News Limited. All Rights Reserved.

[makendon] 26/3/2020 22:39

Ant15, thanks for that, I am already heavily invested. I’m not a ramper either, hopefully just sharing good news from reliable sources.

[ant15] 26/3/2020 22:35

Makendon rest assured this is a real opportunity Very rarely do we see anything like this. Look who has taken large chunks in the placing and has been holding. BUY with capitals BUY I am not ramping to make money on my holding I am simply underscoring the opportunity

[makendon] 26/3/2020 22:24

It’s made the pages of the BMJ :)

www.bmj.com/content/368/bmj.m1252


Interferon β 1a (SNG001)
SNG001 is an inhaled formulation of a drug called interferon β—a molecule that forms part of the lung’s own defence mechanism to fight off viruses. It has been tested in phase two trials for asthma patients and was found to lead to improvements in lung function. In covid-19, the theory has been raised that SNG001 could work by increasing the production of INF-β—thought to be suppressed by coronaviruses—to prevent or decrease symptoms of severe respiratory illness, such as pneumonia.

In the UK, pharmaceutical company Synairgen has been given expedited approval from the Medicines and Healthcare Products Regulatory Agency and Health Research Authority to test the drug for patients with covid-19 in a clinical trial.

Ian Hall, professor of molecular medicine at the University of Nottingham, said, “The idea behind the trial is that by giving more of this molecule to the lung it could help reduce the severity of infection with covid-19, especially in those people who have reduced immune responses to the virus. If the trial shows that interferon beta is a useful treatment for covid-19, it would provide a way to reduce the severity of disease and potentially reduce death rates.”

[bobaxe1] 26/3/2020 20:46

500,000 share today and yesterday

[saint in exile] 26/3/2020 20:34

Yep I concur,looks like placing shares getting sold for a tidy profit.

[tickboo] 26/3/2020 19:05

Looks like a worked sell and I'm a holder too. It's a good thing it's been soaked up. Someone likely to have bought at 35p and made a quick £50,000. Wouldn't surprise me if the entity has kept a decent holding for the possible much larger profit.

[2nell] 26/3/2020 19:04

This drug can't come soon enough for a huge amount of people.
lets hope it does.

[hazl] 26/3/2020 19:01

This share has done well,from a financial point of view,regardless of what their business is(extremely hot) or they would never have been able to get the placing away.
This is common practice when the share is popular.It gives the company much needed
cash just when it is needed, in this case,particularly, I imagine.

It is fine, and perhaps we ought to move on and accept the trades, rather than examining in minutia at this point.

[jev1] 26/3/2020 18:53

No surprise, therefore, that in the RNS, £4 Million of the fundraise is for:

_______



Manufacture of SNG001 drug product and other supply chain considerations GBP4m

[dave444] 26/3/2020 18:49

Plenty of likely news re discussions and potential positive outcomes of those discussions and I don't think it will be very long before we find out!

[jev1] 26/3/2020 18:46

Makendon

Three stand out pieces for me in amongst the Daily Mail write up. :o)

_________


'.... leaving scientists expecting IFN-beta to also protect against the COVID-19 strain.'


'But it does say has been approached by, and is in discussion with, a number of scientific and governmental bodies in the US and internationally since the COVID-19 outbreak began.'


'Mr Marsden said: 'A successful outcome from this trial [at Southampton] in COVID-19 patients would be a major breakthrough in the fight against this coronavirus pandemic.''

________


SNG have a treatment/product that scientists already believe will work against COVID-19 and that world governments have already approached SNG about it.

:o)

[dave444] 26/3/2020 18:29

My agenda?I am a holder!What is your agenda?

[makendon] 26/3/2020 18:27

Dave444

At 16:25 It was a buy at 45.15 for 500,000

What is your agenda here?

[dave444] 26/3/2020 18:23

The 500k was a sell!It is clear on L2 trade prices

[makendon] 26/3/2020 18:18

Jrlomax and dave444,

Don’t know where your are getting your info from? Clearly the number of buys to sells over the day was significantly higher - buy 2.49m sell 1.68m.

[dave444] 26/3/2020 18:09

Clearly a sell!Look at the trades over the course of the day - it was clearly worked presumably when fin cap went on the offer